Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies

Kidney International Reports - Tập 6 Số 5 - Trang 1416-1422 - 2021
Swetha Rani Kanduri1, Wisit Cheungpasitporn2, Charat Thongprayoon2, Tananchai Petnak3,4, Yi Lin5, Karthik Kovvuru1, Sandhya Manohar2, Kianoush Kashani2,3, Sandra M. Herrmann2
1Department of Medicine, Ochsner Medical Center, New Orleans, Louisiana, USA
2Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
3Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
4Division of Pulmonary and Pulmonary Critical Care Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Gill, 2016, Chimeric antigen receptor T cell therapy: 25 years in the making, Blood Rev, 30, 157, 10.1016/j.blre.2015.10.003

Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967

Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226

Thongprayoon, 2020, Diagnostics, risk factors, treatment and outcomes of acute kidney injury in a new paradigm, J Clin Med, 9, 1104

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra225, 10.1126/scitranslmed.3008226

Thông tin
Thông tin xuất bản

Kidney International Reports

Tập 6 Số 5

1416-1422

Thông tin tác giả